January 2021 – StimAire enters Engineering Verification Test (EVT) for its injectable + wearable treatment for Obstructive Sleep Apnea.
July 2020 – StimAire develops an ultrasound-guided needle path for the injectable for Obstructive Sleep Apnea.
June 2020 – Robert Dean MD, Otolaryngologist, joins StimAire’s leadership team.
May 2020 – StimAire develops technology that eliminates the tingling feeling, a side effect and efficacy-limiter of TENS devices. The technology can be applied to TENS treatments for migraine, essential tremor, and opioid withdrawal. This breakthrough is expected to increase acceptance of exisitng TENS devices as well as increase efficacy by enabling stronger stimulation that is easily tolerated.
November 2019 – StimAire closes its Series A Financing that paves the way for clinical testing of its sub-millimeter injectable neural stimulation devices.
October 2019 – StimAire receives and tests custom components that allow the injectable for Obstructive Sleep Apnea to flow through an 18 gauge needle
August 2019 – StimAire completes first form-factor prototype of injectable for treating Obstructive Sleep Apnea that fits through a 14-gauge needle and uses off-the-shelf passive electronics components. A final design of the injectable that fits through an 18-gauge needle was also achieved, using custom components.
July 2019 – Daniel Root MD, founder of Oregon Sleep Associates and founder of sleepdirect.com, is added to StimAire’s Scientific Advisory Board.
May 2019 – Sai Parthasarathy MD and University of Arizona Chief of Pulmonology, is named Principal Investigator of StimAire’s human sleep studies.
May 2019 – Tony Arnold, former CEO of Setpoint Medical, is named Executive Consultant for StimAire.
April 2019 – StimAire completes first form-factor prototype of wearable stimulator for treating Obstructive Sleep Apnea. The prototype hardware is ~2 cm in diameter and ~1 cm thick, and is powered by rechargeable button batteries.
March 2019 – Abhay Sanan MD/Neurosurgeon, is named Chief Medical Officer of StimAire.
November 2018 – Deep Transmission Demonstration StimAire achieved a 10 centimeter transmission depth for its non-surgical, wearable, wireless neural stimulation system. The injectable was placed in a saline bath 10 centimeters deep. The amplitude at the injectable was sufficient for almost all neural stimulation therapies, including for incontinence, pain, and mental illness. The addressable market totals $13 billion. Technical Details: The size of the injectable was close to the final design of 2 millimeters in diameter by 8 millimeters long, and contained only passive components. The thin and lightweight wearable consumed 3.3 watts during stimulation in this experiment. For therapies requiring less than 10 cm transmission depth, the wearable power drops more than proportionately and the injectable and wearable can be made smaller.
October 2018 – First Human OSA Therapy Demonstration StimAire achieved its first human therapy demonstration of its wearable, wireless, non-surgical neural stimulation system. Guided by ultrasound imaging, StimAire’s injectable was connected to a two-electrode needle and placed extraneurally at the hypoglossal nerve. During Stage 2 sleep, a sleep apnea subject experienced a 4X reduction in obstructive events when the stimulation was turned on. Obstructive events were determined by nasal airflow measurements. No changes in systemic indictors, such as blood pressure and heart rate, were recorded during stimulation, and the patient experienced no pain or discomfort. Technical Details: The wireless transmission distance was greater than one centimeter and the wearable power was a small fraction of a watt. The injectable used in the study was close in size to the final design of 1.5 millimeters in diameter by 5 millimeters long and contained only passive components. The wearable used in the experiment was close in size to the final design of 2 centimeters in diameter by 1 centimeter thick.
September 2018 – First-in-Human Demonstration StimAire achieved its first human demonstration of its wearable, wireless neural stimulation system. Two needle electrodes were placed via ultrasound imaging near the hypoglossal nerve and were connected electrically to an (uncommitted) StimAire injectable. The subject’s tongue moved out of the airway during stimulation, effectively achieving sleep apnea treatment. As in prior animal trials, all critical measurements followed precisely that of invasive, wired stimulation, showing that this technology is ready to eliminate surgery for proven neurostimulation treatments. The transmission distance was greater than one centimeter and the wearable power was less than half a watt. The size of the injectable was close to the final design of 1.5 millimeter diameter by 5 millimeters long.
August 2018 – First-in-Animal Demonstration StimAire achieved a successful proof-of-concept of its wearable and non-surgical neurostimulation technology in a small animal. The sciatic nerve of a rat was stimulated by a tiny injectable to produce muscle contractions in the hind leg with indistinguishable characteristics vs. invasive wired stimulation. All key parameters tested successfully including muscle force, response delay, long-term stability, robustness, and consistency. The depth of transmission was greater than one centimeter, and the power consumption of the wearable was less than one watt. The intensity of nerve stimulation achieved extraneurally is sufficient for most human neurostimulation therapies.